DisclosureWe earn commission on partner links; ranking is set by clinician-vetted methodology — not advertisers.
LillyDirect is the manufacturer cash-pay channel for Zepbound. Vial format $349-499/mo depending on dose. Cheapest direct-pay route in the entire GLP-1 category.
Direct-to-patient through Lilly-partnered telehealth platforms (FORM, Truepill). Zepbound vials require manual syringe draw — different from pen format.
LillyDirect Zepbound vials: $349/mo for 2.5-5 mg, $499/mo for 7.5+ mg. Pen formats remain commercial-priced. Requires US prescription.
Lilly allocates vial production preferentially to LillyDirect. Supply has been consistent post-shortage.
Cash-pay only. Manufacturer copay card for insured patients goes through retail pharmacy, not LillyDirect.
Uninsured patients, patients without weight-loss-indication coverage, or anyone wanting the absolute cheapest legitimate Zepbound cash-pay route.
LillyDirect at $349/mo (low dose) or $499/mo (high dose) is the most aggressive manufacturer cash-pay in the category. The vial format adds friction (syringe draw, refrigeration) but the savings justify it for most patients.
Editorial summary. Pricing and inventory shift frequently. Confirm with the pharmacy directly before relying on any single source.